MyFinsight
Home
Blog
About
Contact
Download
Download image
Disposition of investments
in marketable...
$155,277K
Issuance of common shares
pursuant to exercise of...
$5,540K
Issuance of common shares
pursuant to espp
$181K
Proceeds from sale of
property and equipment
$364K
Net cash provided by
investing activities
$15,580K
Net cash provided by
financing activities
$5,721K
Effect of foreign
exchange rate changes on...
$14K
Canceled cashflow
$140,061K
(decrease) / increase in
cash and cash...
-$18,322K
Canceled cashflow
$21,315K
Stock-based compensation
expense
$6,953K
Restructuring, settlement and
impairment provisions
$2,811K
Prepaid expenses and
other assets
-$1,698K
Accounts receivable
-$1,375K
Depreciation and
amortization
$363K
Non-cash interest
expense
$95K
Purchase of investments
in marketable...
$140,061K
Net cash used in
operating activities
-$39,637K
Canceled cashflow
$13,295K
Net loss
-$33,501K
Change in deferred
license revenue
-$10,434K
Net accretion of
investments in marketable...
$2,349K
Accounts payable and
accrued liabilities
-$2,105K
Change in fair value of
contingent consideration
-$1,830K
Non-cash royalty revenue
$1,482K
Gain on sale of
property and equipment
$674K
Other liabilities
-$557K
Back
Back
Cash Flow
source: myfinsight.com
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)